Vascular Solutions to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum

Vascular Solutions to Present at the Canaccord Genuity Medical Technology &
Diagnostics Forum

MINNEAPOLIS, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc.
(Nasdaq:VASC) today announced that the Company is scheduled to present at the
Canaccord Genuity Medical Technology and Diagnostics Forum in New York City on
Thursday, November 14^th at 8:30am (EST).

Howard, Root, Chief Executive Officer of Vascular Solutions, will deliver the
Company's presentation.To hear the live audio webcast of the Vascular
Solutions' presentation, go to the investor relations page of the Company's
web site and click on the "Investor Conferences" icon a few
minutes prior to start time to download any necessary software.

About Canaccord Genuity

Canaccord Genuity is a leading independent financial services firm committed
to fostering the entrepreneurial economy by bringing corporate and
institutional clients a unique perspective on global investment opportunities.
More information is available at

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses
on developing unique clinical solutions for coronary and peripheral vascular
procedures.The company's product line consists of over 75 products in three
categories: catheter products, hemostat products and vein products.Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein specialists
through its direct U.S. sales force and international independent distributor

The information in this press release contains forward-looking statements,
including statements regarding the international availability of the Venture
catheter and expectations about the product's sales, that involve risks and
uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements. Important factors that may
cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2012 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include,
without limitation, risks associated with the need for adoption of our new
products, lack of sustained profitability, exposure to intellectual property
claims, significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by others, doing
business in international markets, the availability of third party
reimbursement, and actions by the FDA.

For further information, connect to

CONTACT: James Hennen, CFO
         Phil Nalbone, VP
         Vascular Solutions, Inc.
         (763) 656-4300
Press spacebar to pause and continue. Press esc to stop.